To our knowledge, this is the first report to show that PtPT, as a novel inhibitor of 26 S proteasome-associated DUBs, is effective against CML cells, including those harboring gate-keeper mutant T315I Bcr-Abl. Here, PTPN2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.